Business
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
BEVERLY HILLS, Calif., Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"BEVERLY HILLS, Calif., Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform is pleased to announce the filing of U.S. and international patent applications, and the initiation of clinical development of TriKE™ therapy for the treatment of HER2+, HER3+ and HER2+/HER3+ heterodimer complex breast and gastrointestinal cancers.\nBuilding upon the success of GTB-3550, where in FDA clinical trials patient #7 showed a 61.7% reduction in cancer cells for high-risk Myelodysplastic Syndromes (HR-MDS), GT Biopharma is expanding the therapeutic utility of its TriKE™ platform to attack solid tumor cancers. The Company's HER2 TriKE is based on its modular therapeutic platform, which is composed of a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-HER2 antibodies, and a modified form of IL-15. The natural killer (NK) cell stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates NK cells and enhances their ability to kill cancer cells.\nAnthony Cataldo, Chairman and Chief Executive Officer of GT Biopharma commented, \"We are pleased our HER2 TriKE™ therapeutic product candidate has shown good efficacy in animal models enabling us to initiate GMP manufacturing for FDA clinical trial development. We anticipate submitting our IND application to FDA next year requesting allowance to proceed with an evaluation in patients with complex breast and gastrointestinal cancers. The TriKE™ platform lends itself to liquid and solid tumors as well as infectious diseases.\" \nHER2, HER3 and HER2/HER3 Heterodimer Complex\nAbout 15% of breast cancer cells have a high density of human epidermal growth factor receptor 2 (HER2) expressed on the cell's surface. The frequency of HER2 overexpression in gastric and gastroesophageal cancer ranges from 4.4% to 53.4%, with a mean of 17.9%1. HER2 is responsible for telling the cell to divide. Cells with too many HER2 receptors divide uncontrollably which causes the cancer to grow. HER3 is another receptor in the same family as HER2 whose levels can also be increased in cancer cells. HER2 and HER3 can bind together, ...